Evidence map›Paper›PMID 29390571›Full record

SynthesisMedicine2017

Association between MDR1 C3435T polymorphism and colorectal cancer risk: A meta-analysis.

Shan-Shan Jin, Wei-Juan Song

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shan-Shan JinDepartment of Oncology Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
Wei-Juan Song
Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe multidrug resistance gene 1(MDR1) C3435T polymorphism has been reported to be associated with colorectal cancer (CRC) risk in Asians, however the results were inconsistent. Thus, we performed a meta-analysis to generate large-scale evidence on the association between C3435T polymorphism and CRC risk in Asian populations.

methodsThe PubMed, Web of Science, Embase, CNKI, and Chinese Biomedicine databases were searched up to January 15, 2017. The odd ratios (ORs) and 95% confidence intervals (95% CIs) were calculated by a fixed-effects or random-effects model. Sensitivity and cumulative meta-analysis were also performed.

resultsA total of 7 studies involving 4818 individuals were included in this pooled-analysis. The results suggested that persons carrying a T allele at the C3435T polymorphism had a significantly decreased risk of CRC in Asian population (T vs C: OR = 0.897, 95%CI = 0.826-0.975, P = .01), and the significant association was also observed in another 2 genetic models (TT vs CC: OR = 0.721, 95%CI = 0.605-0.861, P < .001; TT vs TC+CC: OR = 0.679, 95%CI = 0.579-0.795, P < .001). Moreover, the results of sensitivity and cumulative meta-analysis indicated the stable of our results. Finally, funnel plot and Egger's test showed no evidence of publication bias.

conclusionsIn summary, this meta-analysis provided evidence that MDR1 C3435T polymorphism is associated with a decreased risk of CRC in Asian population.

Indexed as

Asian PeopleATP Binding Cassette Transporter, Subfamily BColorectal NeoplasmsGenetic Predisposition to DiseaseHumansPolymorphism, Single NucleotideRisk FactorsABCB1 protein, humanATP Binding Cassette Transporter, Subfamily B

Identifiers

PMID29390571
PMCPMC5758273
OpenAlexW2779151065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.